If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
177
results.
Updated on
15/11/2026 [08:47:00]
Results 125 to 150 of 177
Absstract of: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Absstract of: US20260297079A1
0000 The present invention relates to an aromatic heterocycle-fused cyclohexyl aminoalkyl piperidine derivative, a preparation method and use thereof. Specifically, the present invention provides a compound of general formula (I), a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor, use thereof for activating the activities of a 5-HT<1A >receptor and dopamine D<2 >and D<3 >receptors, and use thereof in the preparation of a medicament for Parkinson's disease.
0000
Absstract of: US20260297085A1
This disclosure relates to compounds of Formula (I-1) or (I-2): The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2) and are useful for the treatment of diseases or disorders, such as e.g. inflammation, autoimmune disease, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn. The disclosure further provides methods of preparing the compounds.
Absstract of: US20260294875A1
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.
Absstract of: US20260294922A1
The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3; also known as MAPK8, MAPK9, and/or MAPK10), pharmaceutical compositions thereof, and methods of using the same for the treatment, prevention, and/or amelioration of one or more diseases and/or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and/or 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting the disease and/or disorder in the subject with a suitable diagnostic method.
Absstract of: US20260297217A1
0000 Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.
Absstract of: EP4813390A2
Provided herein are compounds according to Formula (I)or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
Absstract of: EP4813985A1
Provided are a compound represented by formula I, a stereoisomer, a deuterated substance, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as the use thereof as a BRAF regulator in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description.
Absstract of: EP4813991A1
Provided are a novel compound, a use thereof for inhibiting the activity of CDK12 and/or CDK13 and degrading cyclin K, a pharmaceutical composition comprising the same, and a use thereof for the treatment of diseases associated with CDK12 and/or CDK13 and/or cyclin K, such as cancer. According to the present invention, the compounds exhibit excellent inhibitory activity and selectivity against CDK12 and/or CDK13, and induce degradation of cyclin K, and thus can be useful for the treatment of cancers such as breast cancer or gastric cancer.
Absstract of: KR20260143072A
본 발명은 화학식 1로 표시되는 화합물을 포함하는 근위축성 측삭경화증(ALS)을 예방, 치료, 또는 개선하는 데 사용하기 위한 조성물 및 이의 용도에 관한 것이다. 본 발명의 조성물은 근위축성 측삭경화증(ALS) 및/또는 관련 증상을 예방, 치료 또는 호전시키는 데 탁월한 효과를 나타낼 수 있다.
Absstract of: AU2025235730A1
The present disclosure is generally directed to tetracyclic analogs that modulate autophagy in a subject suffering from alpha-1 antitrypsin deficiency (ATD) and possibly other autophagy associated diseases or disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
Absstract of: US20260285873A1
The present invention discloses cyclic compounds as multi-target kinase inhibitors and preparation methods thereof. The multi-target kinase inhibitors of the present invention are as shown in general formula I, wherein R1, R2, R3, R3a, L1, L2, L3, ring A, and ring B are as shown in the Specification and Claims. The present invention also discloses preparation methods of general formula I and its inhibitory activity against multiple kinases. The compounds of general formula I described in the present invention can be used for treating cancers and neurodegenerative diseases such as Parkinson's disease, etc.
Absstract of: US20260285954A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Absstract of: US20260287576A1
0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.
Absstract of: US20260285956A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Absstract of: US20260284230A1
0000 Provided herein are compositions and methods of treating and/or preventing amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the methods comprising administering an agent wherein the agent modifies neurons via changes in Kcnn1 protein expression or activity, which in turn modifies neuron firing and/or increases the clearance or protection from toxicity of an ALS-causing protein.
Absstract of: US20260283995A1
0000 What is provided is a method for treating olfactory disorders, multiple sclerosis, metachromatic leukodystrophy, paralysis, sensory disorders, cognitive dysfunction, Alzheimer's disease, amyotrophic lateral sclerosis, schizophrenia, bipolar disorders, stress, fatigue or anxiety disorders, including administering an effective amount of linalyl acetate, α-terpineol or 1,8-cineole to a subject in need thereof.
Absstract of: DE102025111075A1
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von dopaminergen neuronalen Organoiden (d-NOs) mit Nachweis der Dopaminfreisetzung in biologisch wirksamen Konzentrationen. Darüber hinaus umfassen d-NOs neben dopaminergen Neuronen auch funktionell miteinander verbundene GABAerge, glutamaterge und cholinerge Neuronen sowie Gliazellen, wodurch sie zu einem multizellulären Organoid mit einer für das Mittelhirn repräsentativen Zellzusammensetzung und Funktion werden. Daher zeigen die d-NOs der Erfindung eine komplexe Regulation dopaminerger Neuronen durch verwandte exzitatorische und inhibitorische Neuronen, was auf Kontrollmechanismen hindeutet, die beispielsweise eine Überproduktion und Freisetzung von Dopamin verhindern können. Die Erfindung bezieht sich auch auf die n-NOs als Implantat oder zur Verwendung bei der Behandlung der Parkinson-Krankheit. Darüber hinaus bezieht sich die Erfindung auf die Verwendung der d-NOs für Wirkstoffscreenings.
Absstract of: US20260284097A1
0000 The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as Alzheimer's disease (e.g., early onset Alzheimer's disease), using such dsRNAi agents and compositions.
Absstract of: WO2026198526A1
The present disclosure provides compositions and methods for treating a subject afflicted with or at risk of developing a neurological condition, including a synucleinopathy such as Parkinson's disease, increasing mitochondrial function, reducing alpha-synuclein aggregation, and decreasing cellular oxidative stress. Aspects of the disclosure further relate to molybdenum diselenide nanomaterial compositions and combinatorial therapies for neuroprotection.
Absstract of: WO2026198539A1
The present disclosure provides products and methods for modulating brain lipid function and dysfunction in a subject. In some aspects the methods are useful for slowing the progression of or preventing the development of Alzheimer's Disease or for treating Alzheimer's disease. The disclosure provides the results of a genome-wide CRISPR screening to reveal regulators of oligodendrocyte lipid dysfunction.
Absstract of: WO2026193686A1
The present invention belongs to the technical field of biopharmaceutics, and specifically relates to a pharmaceutical composition for preventing and/or treating Alzheimer's disease. Provided in the present invention is an NPAFP protein-based pharmaceutical composition. The composition exhibits significant effects in anti-oxidation, improving mitochondrial quality, reducing the secretion of Aβ42, ameliorating the pathological state caused by Tau PFF, etc., thereby providing a new idea for the prevention and treatment of Alzheimer's disease.
Absstract of: WO2026197766A1
The present invention relates to a composition comprising a compound represented by chemical formula 1 for use in preventing, treating, or ameliorating amyotrophic lateral sclerosis (ALS), and a use thereof. The composition of the present invention can exhibit an excellent effect in preventing, treating, or ameliorating amyotrophic lateral sclerosis (ALS) and/or related symptoms.
Absstract of: US20260284041A1
0000 The purpose of the present invention is to provide a medicinal agent that exhibits the effect of inhibiting aggregation of a causative protein of an HRE-related neurodegenerative disease such as ALS. According to the present invention, rifampicin or a rifampicin compound selected from the group consisting of rifampicin, a derivative thereof, and a salt of rifampicin or the derivative and/or resveratrol or a resveratrol compound selected from the group consisting of resveratrol and a derivative thereof is an active ingredient of a preventive or therapeutic agent for a neurodegenerative disease caused by TDP-43 accumulation, or an active ingredient of a preventive or therapeutic agent for ALS.
Nº publicación: US20260284153A1 24/09/2026
Applicant:
GEMVAX & KAEL CO LTD [KR]
GEMVAX & KAEL CO., LTD.
Absstract of: US20260284153A1
A method for treating periodontal disease, atherosclerosis caused by the periodontal disease, and/or Alzheimer's disease includes administering a composition comprising a peptide having an amino acid sequence of SEQ ID NO: 1 to a subject in need thereof. The composition is effective in suppressing osteoclastogenesis, suppressing Porphyromonas gingivalis colony formation, and suppressing gingipain expression. Further, the composition is safe to a living body and involves less side effects including abnormal response.
BOPI
Electronic site
